company-logoAptorum Group Limited$1.36
%
Analyst Rating: Hold

Stock Details

CEO

Chung Yuen Huen

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

1

Address

17 Hanover Square, London, W1S 1BN

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Top Competitors

Income Statement  

Financials

Selected Year

Revenue Estimates

EPS Estimates

Net Income Estimates

Price target for Aptorum Group Limited  $1.36

$0

Min Forecast(+0% )

$249.61

Avg Forecast( +0% )

$325

Max Forecast(+0%)

EPS

Revenue

Institutional Holder

Loading institutional holder data...

Congress Tracker 

    Showing 0 of 0 results

    Insider Trading of Key Employees

      Showing 0 of 0 results

      Financial News: APM